Mandate

Vinge has advised Stockholm Exergi AB in connection with the conclusion of a permanent carbon removal agreement with Microsoft, the world’s largest to date

May 16, 2024

Vinge has advised Stockholm Exergi in connection with the conclusion of a permanent carbon removal agreement with Microsoft, covering 3.33 million tonnes of permanent carbon removals from bio-energy with carbon capture and storage (BECCS) at Värtan, Stockholm. The agreement is the world’s largest permanent carbon removal deal to date.

When in operation, Stockholm Exergi’s plant will permanently remove up to 800,000 tonnes of CO₂ from the atmosphere per year. The agreement with Microsoft is seen as a milestone for climate change mitigation. By demonstrating commitment to ambitious, voluntary corporate climate objectives, Microsoft and Stockholm Exergi hope to contribute to the much-needed growth of the industry, to allow corporates to meet their net-zero targets and nations to meet the objectives of the Paris Agreement. For more information, please click here.

Vinge's team consisted mainly of Michele Fara and Josua Fridh.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025